Home > Insider Trading > Filing (0001213900-19-001093)

Filing Details

Accession Number:: 0001213900-19-001093
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2019-01-23 10:38:12
Reporting Period:: 2019-01-17

Accepted Time:: 2019-01-23 10:38:12
Original Submission Date:: 2019-01-22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609550	Inspire Medical Systems Inc.	INSP	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1459212	Joyce Erony	C/O Inspire Medical Systems, Inc. 9700 63Rd Avenue North, Suite 200 Maple Grove MN 55369		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-01-17	59,296	$52.66	1,137,043	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-01-17	90,000	$53.86	1,047,043	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-01-17	54,384	$54.08	992,659	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-01-18	35,616	$54.60	957,043	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-01-18	29,204	$55.32	927,839	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-01-22	20,905	$54.00	906,934	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $53.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $55.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.25 to $55.12. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.58 to $55.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $56.685. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.07 to $55.10. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.